

2. TOPIC	Hot Line 1 Press Conference
Title	Hot Line 1
PC Timing	8:00 – 9:00, SUNDAY 30 AUGUST 2009
Chairpersons	Prof R Ferrari (IT) Prof F.J Pinto (PT)
Panel / Presentations	<p>Name: Prof G Fowkes (UK) Presentation: Randomised controlled trial of low dose aspirin in the prevention of cardiovascular events and death in subjects with asymptomatic atherosclerosis.</p> <p>Refers to: HOT LINE I Presentation: 175 Timing: 11:00-12:30 Location: Barcelona Zone 2</p> <hr/> <p>Name: Dr S R Mehta (CA) Presentation: A randomized comparison of a clopidogrel high loading and maintenance dose regimen versus standard dose and high versus low dose aspirin in 25,000 patients with acute coronary syndromes: Results of the CURRENT OASIS 7 Trial.</p> <p>Refers to: HOT LINE I Presentation: 177 Timing: 11:00-12:30 Location: Barcelona Zone 2</p> <hr/> <p>Name: Prof L C Wallentin (SE) Presentation: Comparison of Ticagrelor, the first reversible oral P2Y12 receptor antagonist, with clopidogrel in patients with acute coronary syndromes: results of the PLATelet inhibition and patient Outcomes (PLATO) trial.</p> <p>Refers to: HOT LINE I Presentation: 179 Timing: 11:00-12:30 Location: Barcelona Zone 2</p>
	<p>Name: Dr S J Connolly (CA) Presentation: A randomized trial of dabigatran, a oral direct thrombin inhibitor, compared to warfarin in 18,113 patients with atrial fibrillation at high risk of stroke</p> <p>Refers to: HOT LINE I Presentation: 181 Timing: 11:00-12:30 Location: Barcelona Zone 2</p>

	<p>Name: Dr M Sabatine (US)</p> <p>Presentation: Clinical Efficacy and Safety of Otamixaban, an Intravenous, Selective Factor Xa Inhibitor for the Treatment of Non-ST-Elevation Acute Coronary Syndromes: Results of SEPIA-ACS1 TIMI 42, a multinational, randomized, double-blind, controlled, dose-finding phase IIb study</p> <p>Refers to HOT LINE I</p> <p>Presentation: 183</p> <p>Timing: 11:00-12:30</p> <p>Location: Barcelona Zone 2</p>
--	--